PB Watkins

1.7k total citations · 1 hit paper
10 papers, 1.2k citations indexed

About

PB Watkins is a scholar working on Pharmacology, Oncology and Epidemiology. According to data from OpenAlex, PB Watkins has authored 10 papers receiving a total of 1.2k indexed citations (citations by other indexed papers that have themselves been cited), including 8 papers in Pharmacology, 4 papers in Oncology and 3 papers in Epidemiology. Recurrent topics in PB Watkins's work include Drug-Induced Hepatotoxicity and Protection (7 papers), Drug Transport and Resistance Mechanisms (4 papers) and Pharmacogenetics and Drug Metabolism (4 papers). PB Watkins is often cited by papers focused on Drug-Induced Hepatotoxicity and Protection (7 papers), Drug Transport and Resistance Mechanisms (4 papers) and Pharmacogenetics and Drug Metabolism (4 papers). PB Watkins collaborates with scholars based in United States, United Kingdom and France. PB Watkins's co-authors include Merrie Mosedale, Hajime Takikawa, Mark Avigan, Neil Kaplowitz, Ann K. Daly, Einar S. Björnsson, Raúl J. Andrade, Dominique Larrey, Mariam Molokhia and Guruprasad P. Aithal and has published in prestigious journals such as Gastroenterology, Clinical Pharmacology & Therapeutics and CPT Pharmacometrics & Systems Pharmacology.

In The Last Decade

PB Watkins

10 papers receiving 1.2k citations

Hit Papers

Case Definition and Phenotype Standardization in Drug-Ind... 2011 2026 2016 2021 2011 200 400 600
What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

  1. Case Definition and Phenotype Standardization in Drug-Induced Liver Injury
    2011 713 citations Guruprasad P. Aithal, PB Watkins et al. Clinical Pharmacology & Therapeutics profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
PB Watkins United States 8 904 345 341 296 141 10 1.2k
Camilla Stephens Spain 19 1.0k 1.2× 382 1.1× 324 1.0× 302 1.0× 173 1.2× 44 1.5k
Andreas Benesic Germany 17 449 0.5× 253 0.7× 141 0.4× 287 1.0× 243 1.7× 30 1.1k
Michael P. Holt United States 11 698 0.8× 311 0.9× 193 0.6× 461 1.6× 245 1.7× 12 1.3k
Craig Lammert United States 14 497 0.5× 456 1.3× 195 0.6× 433 1.5× 70 0.5× 55 1.0k
Full‐Young Chang Taiwan 21 641 0.7× 499 1.4× 410 1.2× 468 1.6× 192 1.4× 50 1.6k
Lydiane Pichard‐Garcia France 18 845 0.9× 365 1.1× 519 1.5× 436 1.5× 348 2.5× 27 1.8k
Marina Kacevska Australia 14 373 0.4× 194 0.6× 384 1.1× 109 0.4× 364 2.6× 14 1.2k
Imir G. Metushi United States 15 495 0.5× 123 0.4× 240 0.7× 90 0.3× 232 1.6× 29 1.0k
Masayoshi Tani Japan 16 333 0.4× 158 0.5× 205 0.6× 179 0.6× 161 1.1× 29 825
Eugenia Ulzurrun Spain 9 466 0.5× 178 0.5× 189 0.6× 131 0.4× 86 0.6× 21 674

Countries citing papers authored by PB Watkins

Since Specialization
Citations

This map shows the geographic impact of PB Watkins's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by PB Watkins with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites PB Watkins more than expected).

Fields of papers citing papers by PB Watkins

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by PB Watkins. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by PB Watkins. The network helps show where PB Watkins may publish in the future.

Co-authorship network of co-authors of PB Watkins

This figure shows the co-authorship network connecting the top 25 collaborators of PB Watkins. A scholar is included among the top collaborators of PB Watkins based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with PB Watkins. PB Watkins is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

10 of 10 papers shown
1.
Howell, Brett A., Donald Button, Anthony Caggiano, et al.. (2017). Refining Liver Safety Risk Assessment: Application of Mechanistic Modeling and Serum Biomarkers to Cimaglermin Alfa (GGF2) Clinical Trials. Clinical Pharmacology & Therapeutics. 102(6). 961–969. 30 indexed citations
2.
Stahl, Simone H., et al.. (2017). Systems pharmacology modeling of drug‐induced hyperbilirubinemia: Differentiating hepatotoxicity and inhibition of enzymes/transporters. Clinical Pharmacology & Therapeutics. 101(4). 501–509. 29 indexed citations
3.
Yang, Yuching, et al.. (2016). Elucidating Differences in the Hepatotoxic Potential of Tolcapone and Entacapone With DILIsym ® , a Mechanistic Model of Drug‐Induced Liver Injury. CPT Pharmacometrics & Systems Pharmacology. 5(1). 31–39. 59 indexed citations
4.
Mosedale, Merrie & PB Watkins. (2016). Drug‐induced liver injury: Advances in mechanistic understanding that will inform risk management. Clinical Pharmacology & Therapeutics. 101(4). 469–480. 159 indexed citations
5.
Gerrish, Kevin, et al.. (2015). Blood transcript immune signatures distinguish a subset of people with elevated serum ALT from others given acetaminophen. Clinical Pharmacology & Therapeutics. 99(4). 432–441. 10 indexed citations
6.
Watkins, PB, et al.. (2014). Systems Pharmacology Modeling Predicts Delayed Presentation and Species Differences in Bile Acid–Mediated Troglitazone Hepatotoxicity. Clinical Pharmacology & Therapeutics. 96(5). 589–598. 72 indexed citations
7.
Aithal, Guruprasad P., PB Watkins, Raúl J. Andrade, et al.. (2011). Case Definition and Phenotype Standardization in Drug-Induced Liver Injury. Clinical Pharmacology & Therapeutics. 89(6). 806–815. 713 indexed citations breakdown →
8.
Watkins, PB. (2011). Drug Safety Sciences and the Bottleneck in Drug Development. Clinical Pharmacology & Therapeutics. 89(6). 788–790. 148 indexed citations
9.
Day, CP, Rita Horváth, PB Watkins, et al.. (2009). Common POLG Genetic Variants Increase the Risk of Sodium Valproate Induced Liver Injury and Failure. 2 indexed citations
10.
Kolars, Joseph C., et al.. (1992). Heterogeneity of cytochrome P450IIIA expression in rat gut epithelia. Gastroenterology. 102(4). 1186–1198. 2 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Camilla Stephens Breakdown of academic impact, for papers by Andreas Benesic Breakdown of academic impact, for papers by Michael P. Holt Breakdown of academic impact, for papers by Craig Lammert Breakdown of academic impact, for papers by Full‐Young Chang Breakdown of academic impact, for papers by Lydiane Pichard‐Garcia Breakdown of academic impact, for papers by Marina Kacevska Breakdown of academic impact, for papers by Imir G. Metushi Breakdown of academic impact, for papers by Masayoshi Tani Breakdown of academic impact, for papers by Eugenia Ulzurrun
Rankless by CCL
2026